Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer

BACKGROUND: There is little evidence of abiraterone acetate (AA) plus prednisone for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). In this study, we conducted a comparative analysis of real‐world survival outcomes between AA plus prednisone and enzalutamide (Enz) in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsujino, Takuya, Tokushige, Satoshi, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Saruta, Masanobu, Ohno, Takaya, Nakamori, Keita, Maenosono, Ryoichi, Nishimura, Kazuki, Yamazaki, Shogo, Uchimoto, Taizo, Yanagisawa, Takafumi, Mori, Keiichiro, Urabe, Fumihiko, Tsuzuki, Shunsuke, Iwatani, Kosuke, Yamamoto, Shutaro, Takahara, Kiyoshi, Inamoto, Teruo, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Azuma, Haruhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587977/
https://www.ncbi.nlm.nih.gov/pubmed/37706578
http://dx.doi.org/10.1002/cam4.6536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587977/
https://www.ncbi.nlm.nih.gov/pubmed/37706578
http://dx.doi.org/10.1002/cam4.6536

Ejemplares similares